192 related articles for article (PubMed ID: 27798825)
1. Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.
Kattel K; Mondal G; Lin F; Kumar V; Mahato RI
Mol Pharm; 2017 May; 14(5):1365-1372. PubMed ID: 27798825
[TBL] [Abstract][Full Text] [Related]
2. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
3. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
4. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
6. Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Chitkara D; Mittal A; Behrman SW; Kumar N; Mahato RI
Bioconjug Chem; 2013 Jul; 24(7):1161-73. PubMed ID: 23758084
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice.
Kumar V; Mundra V; Peng Y; Wang Y; Tan C; Mahato RI
Theranostics; 2018; 8(15):4033-4049. PubMed ID: 30128034
[No Abstract] [Full Text] [Related]
8. Co-delivery of gemcitabine and cisplatin via Poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) micelle to improve the in vivo stability and antitumor effect.
Ding N; Zhao Z; Yin N; Xu Y; Yin T; Gou J; He H; Wang Y; Zhang Y; Tang X
Pharm Res; 2021 Dec; 38(12):2091-2108. PubMed ID: 34893950
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
10. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
11. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Almawash SA; Mondal G; Mahato RI
Pharm Res; 2018 Jan; 35(1):17. PubMed ID: 29305793
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.
Liang TJ; Zhou ZM; Cao YQ; Ma MZ; Wang XJ; Jing K
Int J Pharm; 2016 Nov; 513(1-2):564-571. PubMed ID: 27613255
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
14. Stereocomplex Prodrugs of Oligo(lactic acid)
Tam YT; Huang C; Poellmann M; Kwon GS
ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
[TBL] [Abstract][Full Text] [Related]
15. Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate.
Chu W; Tian P; Ding N; Cai Q; Li J; Zhuo X; Tang Z; Gou J; Yin T; Zhang Y; He H; Tang X
Pharm Res; 2018 Oct; 35(12):230. PubMed ID: 30327887
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
17. Poly (l-glutamic acid)-g-methoxy poly (ethylene glycol)-gemcitabine conjugate improves the anticancer efficacy of gemcitabine.
Yang C; Song W; Zhang D; Yu H; Yin L; Shen N; Deng M; Tang Z; Gu J; Chen X
Int J Pharm; 2018 Oct; 550(1-2):79-88. PubMed ID: 30138704
[TBL] [Abstract][Full Text] [Related]
18. Polymeric modification of gemcitabine via cyclic acetal linkage for enhanced anticancer potency with negligible side effects.
Takemoto H; Inaba T; Nomoto T; Matsui M; Liu X; Toyoda M; Honda Y; Taniwaki K; Yamada N; Kim J; Tomoda K; Nishiyama N
Biomaterials; 2020 Mar; 235():119804. PubMed ID: 31991339
[TBL] [Abstract][Full Text] [Related]
19. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
20. Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy.
Xin X; Kumar V; Lin F; Kumar V; Bhattarai R; Bhatt VR; Tan C; Mahato RI
Sci Adv; 2020 Nov; 6(46):. PubMed ID: 33177098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
